

SPECIALTY PHARMACY

Immune Globulin Enrollment Form Phone: 1-877-437-9012 Fax 1-877-309-0687

□ New to Therapy
□ Current Therapy

Patient Information	Clinical Information and Prescription					
Patient Name:	Prior Treatments with duration an	nts Allergies: ase indicate) Patient Height: r discontinuation ts? If so, what brand of IG?				
Home Phone:	Medication Strength/Formulation Directions					
Please attach copy of front and back of patient's prescription ins. card(s) if applicable Insurance Company Name: Insurance Company Phone: Policyholder: Policy holder Employer: Relationship to Patient: ID# Group# RxBIN:	 Bivigam® 10% Gammagard® liquid 10% Gammagard® S/D □ 5% □ Gammaked™ 10% Gammaplex® □ 5% □ 10% Gamunex®-C 10% Hizentra 20% □ PFS □ SD Octagam® □ 5% □ 10% 	6	Infuse grams OR grams per kg OR mg per kg everyweeks □ Divide total dose over days (where clinically appropriate, round to the nearest vial size)	Route: SQ IV Vascular access: Peripheral Central Port Infusion method: Gravity Pump		ort
Prescriber Information Practice/ Organization Name:					itial and maintenance infusions ufacturer's product labeling.	
Physician Name:	Dose		Directions		Quantity	Refills
Address: City: State: Zip: Phone#: Fax#:	□ Acetaminophen □ 325mg □ 500mg □ Diphenhydramine □ 25mg □ 50mg	Maximum	□ Take mg p.o. 30-60min. prior to inf. and q4-6hr prn. □ Qty: □ 11 Maximum of 4 doses in 24 hrs. □			
	□ Epinephrine □ 0.3mg auto-injector □ 0.15mg auto-injector	Inject IM p	Inject IM p.r.n anaphylaxis			
	□ NaCl 0.9% 10ml flush	Flush line with 10ml, before and after infusion and p.r.n line care.			□ Qty:	□ 11 □
SKILLED NURSING visit to establish venous access, provide patient education related	 Heparin 100U/ml 5ml PFS *for central line patients 	Flush line with 5ml after final saline flush.			□ Qty:	□ 11 □
to therapy and disease state, administer medication as prescribed, and assess general status and response to therapy. Frequency based on prescription dose orders.	Emla cream- lidocaine 2.5% /prilocaine 2.5%	Apply topi infusion.	cally to needle insertion site, 30-60 minutes	prior to	□ Qty:	□ 11 □
Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.	☐ Hydration fluid	0.9% NS mL infused over minutes Timing: minutes _ pre IG _ post IG _ during IG			□ Qty:	□ 11 □
	□Other:	□ Sig:			□ Qty:	
	X Physician Signature (no stamp	os) For No	Substitution allowed, please indicate "D	AW" here	Date: /	_/